Hydrogen Sulfide

Hydrogen Sulfide

SCHEMBL4766795

[46SH2]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL28214043 0.71
Phosphine SCHEMBL30340926 0.71
Bromide SCHEMBL28299354 0.71
Hydrochloric Acid SCHEMBL3980396 0.71
SCHEMBL31148891 0.71
Potassium Ion SCHEMBL23462163 0.00 CA4 (0.50)
SCHEMBL25435013 0.00
SCHEMBL25435790 0.00
SCHEMBL25436537 0.00
Ammonia Solution, Strong SCHEMBL25435623 0.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024102332-A1 VACCINE COMPOSITIONS COMPRISING A NEOANTIGEN OF KRAS HIMV LLC (US) 2024-05-16 WO disclosed
EP-3619530-A1 SYSTEMS AND METHODS FOR POST-HARVEST CROP QUALITY AND PEST MANAGEMENT Centaur Analytics, Inc. (US) 2020-03-11 EP disclosed
EP-3615701-A2 SHAPE MEMORY ARTICLES AND METHODS FOR CONTROLLING PROPERTIES Medtronic Inc. (US) 2020-03-04 EP disclosed
WO-2019006466-A1 COMPOSITIONS AND METHODS FOR LARGE-SCALE IN VITRO PLANT BIOCULTURE BOOSHOOT LLC (US) 2019-01-03 WO disclosed
WO-2018204400-A1 SYSTEMS AND METHODS FOR POST-HARVEST CROP QUALITY AND PEST MANAGEMENT Centaur Analytics, Inc. (US) 2018-11-08 WO disclosed
WO-2018201111-A2 SHAPE MEMORY ARTICLES AND METHODS FOR CONTROLLING PROPERTIES MEDTRONIC INC. (US) 2018-11-01 WO disclosed
EP-3384024-A2 MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY Crispr Therapeutics AG (CH) 2018-10-10 EP disclosed
EP-3302382-A1 IMPLANT FOR TREATMENT OF AN OCULAR CONDITION ALLERGAN, INC. (US) 2018-04-11 EP disclosed
WO-2017093804-A2 MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY CRISPR THERAPEUTICS AG (CH) 2017-06-08 WO disclosed
WO-2016196365-A1 IMPLANT FOR TREATMENT OF AN OCULAR CONDITION ENVISIA THERAPEUTICS, INC. (US) 2016-12-08 WO disclosed
EP-1979329-A2 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2008-10-15 EP disclosed
WO-2007089768-A2 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM EXELIXIS, INC. (US) 2007-08-09 WO disclosed
WO-2007047569-A1 VIRTUAL ENVIRONMENTS LEVIATHAN ENTERTAINMENT (US) 2007-04-26 WO disclosed